Vioquest Pharmaceuticals, Inc. - Current report filing (8-K)
September 11 2008 - 4:19PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(
d
)
OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): September 10, 2008
VioQuest
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-16686
|
58-1486040
|
|
(State
or other jurisdiction of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
180
Mt. Airy Road, Suite 102
Basking
Ridge, NJ 07920
(Address
of principal executive offices)
(908)
766-4400
(Registrant's
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
On
September 9, 2008, VioQuest Pharmaceuticals, Inc. (the “Company”) received a
determination from the U.S. Food and Drug Administration that Xyfid™ (1% uracil
topical) is a drug rather than a device and would be regulated with the Center
for Drug Evaluation and Research as opposed to the Center for Devices and
Radiologic Health. Thus, Xyfid is not eligible for marketing clearance pursuant
to the 510(k) process, but the Company will continue its parallel development
of
Xyfid for the prevention of hand-foot syndrome.
On
September 10, 2008, the Company released the press release filed herewith as
Exhibit 99.1 to this Current Report on Form 8-K and the press release is
incorporated herein by reference.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
|
|
99.1
|
Press
release of the Company dated September 10,
2008.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
VioQuest
Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
Date:
September 11, 2008
|
By:
|
/s/
Christopher P. Schnittker
|
|
|
|
Christopher
P. Schnittker
|
|
|
|
Vice
President &
Chief
Financial Officer
|
|
|
|
|
VioQuest Pharmaceuticals (CE) (USOTC:VOQP)
Historical Stock Chart
From Nov 2024 to Dec 2024
VioQuest Pharmaceuticals (CE) (USOTC:VOQP)
Historical Stock Chart
From Dec 2023 to Dec 2024
